Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis | Zendy

Peter Hammerer | Zendy; Manfred P. Wirth | Zendy

Open Access

Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis

Author(s) -

Peter Hammerer,

Manfred P. Wirth

Publication year - 2017

Publication title -

urologia internationalis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.771

H-Index - 53

eISSN - 1423-0399

pISSN - 0042-1138

DOI - 10.1159/000479434

Subject(s) - medicine , leuprorelin , prostate cancer , androgen deprivation therapy , quality of life (healthcare) , hormone therapy , testosterone (patch) , prostate specific antigen , cancer , gynecology , urology , surgery , hormone , breast cancer , luteinizing hormone , gonadotropin releasing hormone , nursing

We investigated the health-related quality of life (HRQoL) of long-term prostate cancer patients who received leuprorelin acetate in microcapsules (LAM) for androgen-deprivation therapy (ADT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research